• Accueil >
  • Publications >
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

1 janv. 2015Annals of Oncology

DOI : 10.1093/annonc/mdu486

Auteurs

I.E. Krop, N.U. Lin, K. Blackwell, E. Guardino, J. Huober, M. Lu, D. Miles, M. Samant, M. Welslau, V. Diéras